Lilly And J&J Back T-Therapeutics’ $133m Bet On TCR Bispecifics Beyond Cancer
T-Therapeutics' ability to validate its platform in humans will be the next test of its ambitions across oncology and autoimmune diseases.
Scrip - November 5, 2026

Forex Again Lifts Major Japanese Firms’ Results
Major Japanese firms report a generally positive quarter helped by forex effects, leading Takeda and Shionogi to revise upwards their guidance for the full fiscal year.
Scrip - November 5, 2026

Smith+Nephew Confirms J&J Talks Ended As US Knee And Hip Decline Continues
Smith+Nephew confirmed it approached J&J about a DePuy Synthes combination but those talks have ended. The company is now pursuing other options for orthopedics — while its US knee and hip business continues to decline and guidance has been cut again.
Medtech Insight - November 5, 2026

Times Up For Indian Toothpaste Manufacturer Using Color Additive Unallowed In US For 60 Years
Pritam International used color additive identified as “CI 14720,” also known as Ext. D&C Red No. 10, Acid Red No. 14, Food Red 3, Carmoisine or Azorubine and delisted since 1966, in Brush Buddies, evo and ARU children’s and other toothpastes available in US.
HBW Insight - November 5, 2026

Toothpaste, Hair Regrowth Recalls Hit US Market; EU Panel Sets Limits For Two Fragrance Ingredients
Recent beauty regulatory news includes US recalls of more than four million tubes of toothpaste and about 11,000 hair regrowth products, while an EU scientific committee found two fragrance ingredients safe at set limits.
HBW Insight - November 5, 2026

Teva Builds On Samsung Bioepis Alliance With Another Two Products As Biosimilars Exceed Expectations
As Teva announced a significant expansion of its biosimilars alliance with Samsung Bioepis, the firm also reported that it was on track to hit its $800m biosimilars sales target for 2027 a year early, helping to partly offset a generics slide due to lower US lenalidomide turnover.
Generics Bulletin - November 4, 2026

FDA Tentative Approval Clears Path For Dr Reddy’s Launch Of Generic Lenacapavir In 120 Countries
With the FDA’s tentative approval now secured, first supplies of Dr Reddy’s generic lenacapavir long-acting injection for HIV prevention are expected to reach LMICs before the end of 2026, while broader rollout is expected next year.
Generics Bulletin - November 4, 2026

Mapping Out Big Pharma’s Obesity Shopping List Beyond The Incretin Rush
With independent late-stage incretin programs thinning, big pharma could look at mechanisms that complement existing weight loss drugs or address their limitations.
In Vivo - November 3, 2026

Strategic Intent: How Circio Rebuilt Itself Around Circular RNA
Most biotech companies spend their time creating value. Far fewer have to figure out how to rebuild it. Erik Wiklund, CEO of Norwegian biotech Circio, has done both.
In Vivo - November 3, 2026